New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
07:57 EDTVRXValeant sees FY13 impact from generics >$100M in revenues
Sees $40M-$50M in revenue declines as a result of planned divestitures. Sees Efinaconazole launch breakeven in 2013. Sees FY13 Solodyn revenue $250M-$275M.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
18:04 EDTVRXSalix confirms FDA Approval of Xifaxan for treatment of IBS-D
Subscribe for More Information
16:59 EDTVRXFDA approves Salix-marketed Xifaxan
The FDA approved Viberzi and Xifaxan, two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea, or IBS-D, in adult men and women. Xifaxan is marketed by Salix Pharmaceuticals, which was acquired by Valeant Pharmaceuticals. Reference Link
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use